Advertisement

Atrial fibrillation as a risk factor for stroke recurrence

      Abstract

      Background

      Although atrial fibrillation is a well-known risk factor for ischemic stroke, the extent to which it increases the risk of stroke recurrence, particularly in elderly patients, is less certain.

      Methods

      We performed a retrospective cohort study of 915 patients aged 50 to 94 years who were admitted with an ischemic stroke. The rates of recurrent strokes and recurrent severe strokes were estimated with the Kaplan-Meier method. The effects of atrial fibrillation on stroke risk were analyzed with proportional hazards models.

      Results

      Of the 829 patients who survived the initial hospitalization, 163 (20%) had a stroke during follow-up. Of the 203 patients with atrial fibrillation during index hospitalization who were not anticoagulated, 54 (27%) had recurrent strokes, compared with 18% (19/103) among those with atrial fibrillation who were anticoagulated and 17% (90/523) among those without atrial fibrillation. The age-adjusted hazard ratio for recurrent stroke among those with atrial fibrillation who were not treated with anticoagulants was 2.1 (95% confidence interval [CI]: 1.4 to 2.9; P <0.001), whereas the hazard ratio for recurrent severe stroke was 2.4 (95% CI: 1.6 to 3.6; P <0.001). The increased risk was observed even in patients aged ≥80 years and persisted during the follow-up for more than 5 years.

      Conclusion

      Atrial fibrillation was an independent risk factor for stroke recurrence over a wide age range.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hart R.G.
        • Benavente O.
        • McBride R.
        • Pearce L.A.
        Antithrombotic therapy to prevent stroke in patients with atrial fibrillation.
        Ann Intern Med. 1999; 131: 492-501
        • Go A.S.
        • Hylek E.M.
        • Phillips K.A.
        • et al.
        Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation. The Anticoagulation Risk Factors in Atrial Fibrillation (Atria) Study.
        Circulation. 2000; 102: 11-13
        • Pearce L.A.
        • Hart R.G.
        • Halperin J.L.
        Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation.
        Am J Med. 2000; 109: 45-51
        • EAFT Study Group
        Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
        Lancet. 1993; 342: 1255-1262
        • Ezekowitz M.D.
        • Bridgers S.L.
        • James K.E.
        • et al.
        Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
        N Engl J Med. 1992; 327: 1406-1412
        • Lai S.M.
        • Alter S.M.
        • Friday M.
        • Sobel G.E.
        A multifactorial analysis of risk factors for recurrence of ischemic stroke.
        Stroke. 1994; 25: 958-962
        • Jorgensen H.S.
        • Nakayama H.
        • Reith J.
        • et al.
        Stroke recurrence.
        Neurology. 1997; 48: 891-895
        • Sacco R.L.
        • Shi T.
        • Zamanillo M.C.
        • Kargman D.E.
        Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community.
        Neurology. 1994; 44: 626-634
        • Kaarisalo M.
        • Immonen-Raiha P.
        • Marttila R.J.
        • et al.
        Atrial fibrillation in older stroke patients.
        J Am Geriatr Soc. 1997; 45: 1297-1301
        • Petty G.W.
        • Brown Jr, R.D.
        • Whisnant J.P.
        • et al.
        Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989.
        Neurology. 1998; 50: 208-216
        • Prencipe M.
        • Culasso F.
        • Rasura M.
        • et al.
        Long-term prognosis after a minor stroke. 10-year mortality and major stroke recurrence rates in a hospital-based cohort.
        Stroke. 1998; 29: 126-132
        • Gustafsson C.
        • Britton M.
        Pathogenetic mechanism of stroke in non-valvular atrial fibrillation: follow-up of stroke patients with and without atrial fibrillation.
        J Intern Med. 1991; 230: 11-16
        • Hankey G.J.
        • Slattery J.M.
        • Warlow C.P.
        The prognosis of hospital-referred transient ischaemic attacks.
        J Neurol Neurosurg Psychiatry. 1991; 4: 793-802
        • Hart R.G.
        • Boop B.S.
        • Anderson D.C.
        Oral anticoagulants and intracranial hemorrhage. Facts and hypothesis.
        Stroke. 1995; 26: 1471-1477
        • Palareti G.
        • Leali N.
        • Coccheri S.
        • et al.
        Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.
        Lancet. 1996; 348: 423-428
        • Landefeld C.S.
        • Beyth R.J.
        Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention.
        Am J Med. 1993; 95: 315-328
        • Evans A.
        • Perez I.
        • Yu G.
        • Kalra L.
        Secondary stroke prevention in atrial fibrillation. Lessons from clinical practice.
        Stroke. 2000; 32: 2106-2121
        • Kalra L.
        • Yu G.
        • Perez I.
        • et al.
        Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness.
        BMJ. 2000; 320: 1236-1239